Critical

Invasive candidiasis / candidaemia (Candida bloodstream infection; incl. C. auris)

Unexplained sepsis in ICU/line/TPN host; echinocandin first-line, remove lines, fundoscopy · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Bloodstream and deep-seated Candida infection, a major ICU/nosocomial killer. Risk: central lines, TPN, broad-spectrum antibiotics, abdominal surgery, neutropenia, haemodialysis, prior colonisation. Often presents as culture-negative sepsis not responding to antibacterials. IDSA 2016: start an ECHINOCANDIN first-line, remove/replace catheters, perform dilated fundoscopy, and seek deep foci (endocarditis, abscess). C. auris is multidrug-resistant and needs strict isolation.

Red flags

  • Septic shock / multi-organ failure
  • Persistent candidaemia >72h on therapy - deep focus (endocarditis, thrombophlebitis, undrained abscess)
  • Prosthetic valve / intracardiac device / endophthalmitis
  • Neutropenia
  • C. auris (MDR) - isolate and alert infection control

Assessment

Differential diagnosis

  • Bacterial sepsis / line infection
  • Other fungaemia (Cryptococcus, moulds)
  • Culture-negative endocarditis
  • Non-infective SIRS
  • Intra-abdominal sepsis

Investigations

  • Blood cultures (sensitivity limited ~50%) - repeat daily/alternate days to document clearance
  • Non-culture markers: beta-D-glucan (non-specific), T2Candida/PCR where available
  • Species identification + antifungal susceptibility (azole/echinocandin resistance; flag C. auris, C. glabrata, C. krusei)
  • Dilated fundoscopy for endophthalmitis/chorioretinitis (changes management/duration)
  • Echocardiography (TOE) if persistent candidaemia / prosthetic valve / line - endocarditis
  • Source imaging (abdomen) for deep candidiasis; assess all intravascular catheters

Management

  • Resuscitate per sepsis bundle; start empirical antifungal early in high-risk septic patient not responding to antibacterials
  • First-line: echinocandin for all candidaemia (IDSA 2016), neutropenic and non-neutropenic
  • Remove/replace intravascular catheters promptly (strongest modifiable factor in non-neutropenic candidaemia)
  • Perform dilated fundoscopy (within first week); step down to fluconazole once stable, susceptible species and clearing
  • Duration: 14 days from first negative blood culture AND resolution of signs (longer for endophthalmitis, endocarditis, osteomyelitis, undrained foci)
  • C. auris / suspected: single-room isolation, contact precautions, inform infection control; treat as echinocandin first-line but confirm susceptibility
  • Source control of any abscess/deep focus

Drugs & doses

Echinocandin FIRST-LINE: caspofungin 70 mg IV load then 50 mg IV OD; OR anidulafungin 200 mg IV load then 100 mg OD; OR micafungin 100 mg IV OD
Step-down: fluconazole 800 mg (12 mg/kg) IV/PO load then 400 mg (6 mg/kg) OD if susceptible species, stable, clearing
Lipid amphotericin B 3-5 mg/kg IV OD if echinocandin intolerance/resistance or CNS/urinary involvement
Voriconazole 6 mg/kg IV BD x2 then 3-4 mg/kg BD for selected (e.g. C. krusei, step-down, ocular) [verify local]
C. auris: echinocandin first-line (many azole/amphotericin resistant); treat per susceptibilities
Neutropenic candidaemia: echinocandin or lipid amphotericin B first-line; manage with haematology

Disposition

Admit (usually ICU/HDU) for antifungal therapy, line removal and source control. ID/microbiology and infection-control involvement; ophthalmology for fundoscopy. Prolonged therapy with follow-up cultures and search for metastatic foci.

Complications & pitfalls

  • Candida endophthalmitis -> blindness
  • Infective endocarditis, septic thrombophlebitis, mycotic aneurysm
  • Metastatic abscesses (hepatosplenic, renal, osteoarticular)
  • Septic shock, high attributable mortality
  • Outbreaks (C. auris) in critical care

Exam pearls

  • Culture-negative sepsis not responding to antibacterials in a line/TPN/ICU host = think candidaemia and start an echinocandin
  • IDSA 2016 made echinocandins first-line over fluconazole for candidaemia - don't wait for species if the patient is unwell
  • Remove the central line - it is the most important modifiable factor in non-neutropenic candidaemia
  • Always do dilated fundoscopy and repeat blood cultures to document clearance; count 14 days from the first negative
  • C. auris is multidrug-resistant and highly transmissible - isolate immediately and inform infection control

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.